top button
    Got Questions


Global IoT Summit 2018
Oct 31, 2018
The Leela Palace, Bangalore



    Connect to us
      Facebook Login
      Site Registration Why to Join

Facebook Login
Site Registration

Veterinary Therapeutics Market Share : Value Chain, Stakeholder Analysis and Trends

0 votes
4 views

The global market for veterinary therapeutics is consolidated in nature and is predicted to remain in the similar situation in the next few years, states a new market intelligence study by Transparency Market Research. The top ten companies that are operating in the market are expected to account a share of more than 75% of the overall market in the coming years. The leading players in the market are focusing on the expansion of the product portfolio, which is anticipated to generate promising growth opportunities for the market players throughout the forecast period.

In addition to this, the rising number of mergers and acquisitions is another key factor encouraging the growth of the global veterinary therapeutics market in the near future. Some of the key players that are operating in the veterinary therapeutics market across the globe are Zoetis, Inc., Bayer Animal Health, Inc., Boehringer Ingelheim Vetmedica, Dechra Animal Health, Virbac S.A., Elanco Animal Health, Merck Animal Health, Merial Animal Health, Ceva Sante Animale, and Vetoquinol S.A.

According to the market research study by Transparency Market Research, in 2015, the global market for veterinary therapeutics was worth US$26.9 bn and is projected to reach a value of US$50.2 bn by the end of 2024. The market is estimated to register a healthy 6.70% CAGR between 2016 and 2024.

Request Sample of Veterinary Therapeutics Market Report –

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=14048

North America and Europe to Register Strong Growth in Near Future

From a regional perspective, Europe and North America are anticipated to witness substantial growth throughout the forecast period. The presence of the leading players and the existence of superior animal health care base are anticipated to accelerate the growth of the North America market in the next few years. In addition to this, the rising trend of the pet ownership and the increasing awareness among people considering the health of their pets are further projected to enhance the growth of the market throughout the forecast period. Furthermore, the rising number of investments and the research and development activities that are being supported by private and government organizations are expected to offer potential growth opportunities for the players in the veterinary therapeutics market across the globe.

The global veterinary therapeutics market has been categorized on the basis of product type into drugs, vaccines, and feed additives. Among these, the drugs segment is projected to account for a major share of the global market throughout the forecast period. The easy availability of drugs and the growing demand for these drugs for preventive measures against several infectious diseases are some of the major factors that are predicted to accelerate the growth of this segment in the next few years. In addition to this, the growing demand for anti-inflammatory drugs is another key factor, which is projected to enhance the growth of the market in the forecast period.

Request for a Discount on Veterinary Therapeutics Market Report –

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=14048

High Demand for Meat to Drive Global Veterinary Therapeutics Market  

A tremendous rise in the population and the growing demand for food are considered as the key factors that are estimated to enhance the growth of the veterinary therapeutics market in the next few years. The rising preference of consumers for different meat and livestock products is further predicted to encourage the growth of the global veterinary therapeutics market in the next few years. On the other hand, the stringent rules and regulations and the less returns on the research and development activities are projected to restrict the growth of the veterinary therapeutics market in the next few years.

More Trending Reports by Transparency Market Research –

Breast Pumps Market: globenewswire.com/news-release/2018/08/23/1555918/0/en/Breast-Pumps-Market-to-Rise-to-US-4-164-6-mn-by-2025-Says-TMR.html

Atrial Fibrillation Market: globenewswire.com/news-release/2019/06/17/1869644/0/en/Atrial-Fibrillation-Market-to-collect-US-10-925-1-million-revenue-by-2026-TMR.html

Eyewear Market: finance.yahoo.com/news/rising-prevalence-chronic-eye-diseases-113000101.html

posted Feb 12 by Bella Watson

  Promote This Article
Facebook Share Button Twitter Share Button Google+ Share Button LinkedIn Share Button Multiple Social Share Button

Related Articles
0 votes

Chagas disease also known as American trypanosomiasis, was discovered by the Brazilian physician Carlos Chagas, in 1909. The Trypanosoma Cruzi parasite transmits the infectious disease to humans and animals. The disease is spread by insect vectors known as Triatominae or kissing bugs. Neglected parasitic infection (NPI) is a group of five parasitic diseases. Chagas disease in one of the NPI in the United States, targeted by the Centers for Disease Control and Prevention for community health action.

Report Overview @ https://www.transparencymarketresearch.com/chagas-disease-treatment-market.html

According to the World Health Organization’s report 2017, about six to seven million people are infected with Chagas disease, mostly in Latin America. Trypanosoma Cruzi parasites are mainly spread by urine/feces of infected blood sucking triatominae bugs. Triatominae bugs, carrying these parasites, live in the roof or wall cracks of houses. These insects hide during the day and are active at night, biting any uncovered areas of the skin.

Parasites from these bugs enter the human body when the individual unconsciously smears the bug’s excreta into the eyes, mouth, or inflamed skin. The disease also spreads through blood transfusion from an infected blood donor, laboratory accidents, organ transplanted from an infected donor, and by consuming foods contaminated with Trypanosoma Cruzi. An infected mother can pass the disease on to her child at the time of pregnancy or childbirth.

Chagas disease shows symptoms in two phases. The first or acute phase of symptoms lasts nearly two months after the infection. In this acute phase, large number of parasites circulates in systemic circulation. Symptoms in this stage are either mild, absent, or non-specific. In around 50% of people bitten by the triatominae bug, first visible indication is a purplish inflammation of an eyelid or skin lesion.

Request PDF Sample of Chagas Disease Treatment Market Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=30458

Moreover, other indications include enlarged lymph glands, fever, muscle pain, swelling, headache, pallor, difficulty in breathing, and chest or abdominal pain. The second phase is the chronic phase. Parasites hide in the digestive muscles and heart. Nearly 10% of the patients suffer from neurological, digestive (usually enlargement of colon or esophagus), or mixed modifications. If neglected, it can lead to sudden death caused by progressive heart failure or cardiac arrhythmias owing to the damage caused to the cardiac muscles and the nervous system.

Chagas disease is detected by observing the parasite in blood smear by microscopic examination. Diagnosis can be made by two different serological tests. Lacks of nutrition (micronutrient and protein-energy malnutrition) exert a direct effect on the Chagas disease infection cause by Trypanosoma Cruzi, and rising the growth of Chagas disease treatment market. Lack of awareness about need for treatment of the disease and limited availability of treatment and medication can restrain the market growth.

Pre Book “Chagas Disease Treatment Market” Research Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=30458&ltype=S

Chagas disease treatment market is segmented into three major categories: based on treatment, end-user, and region. In terms of treatment, the market is divided into two categories, medication and other possible treatments. Based on end-user, the market is bifurcated into hospital and clinical laboratories. Geographically, the global Chagas disease treatment market is divided into four broad regions: North America, Latin America, Asia Pacific, and Rest of the World. Latin America market is expected to grow significantly due to high prevalence rate of the disease, and increasing awareness about disease.

Key players operating in the global Chagas disease treatment market are Johnson & Johnson, KaloBios Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., ELEA SACIF Laboratory, and Bayer AG.

More Trending Reports by Transparency Market Research –

Shock Wave Therapy Device Market: prnewswire.com/news-releases/shock-wave-therapy-device-market-to-reach-us-1399-mn-by-2025-orthopedic-and-urology-application-leads-the-market-677627753.html

Life Sciences BPO Market: prnewswire.com/news-releases/life-sciences-bpo-market-is-expected-to-touch-us286-3-billion-by-2023—says-tmr-300813081.html

0 votes

The high concentration of international as well as regional companies has made the vendor landscape of the global oral contraceptive pills market highly competitive, observes a recent market research report by Transparency Market Research. To gain a stronger hold on the market, companies are seen focusing on untapped regional markets with vast unmet needs. Companies have also increased their focus on ways of improving visibility of their products in emerging market through ploughing more funds into innovative marketing strategies to gain the attention of masses towards the benefits of contraceptives in conservative regions.

Some of the leading companies in the market are Allergan (Actavis) plc., Teva Pharmaceutical, Alkem, Taj Pharma, and Zydus Alidec. According to the report, the global oral contraceptive pills market is expected to rise to a valuation of US$22.9 bn by 2023.

Request PDF Sample of Oral Contraceptive Pills Market Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=8323

Combinations Oral Contraceptive Pills Remain Most Popular

Based on the type of medication, the segment of combination oral contraceptive pills remains one of the leading and most lucrative segments and is likely to rise to a valuation of US$18 bn by 2023. The segment is also expected to surpass other segments in terms of growth rate, continuing to account for a significant share in the overall market by the end of the report’s forecast period.

Geographically, the market in North America is expected to continue to dominate the global market over the forecast period. The market in Asia Pacific, however, is expected to emerge as the most promising regional market in terms of new growth opportunities. Factors such as high population, increased awareness regarding the need for contraceptives for birth control and the easy availability of oral contraceptives as a convenient way of birth control are expected to work in favor of the regional market.

Government Initiatives Aimed at Spreading Awareness to Aid Growth

Some of the key factors driving the global oral contraceptive pills market include a stark rise in the prevalence of unwanted pregnancies, among married as well as unmarried women globally, increased awareness regarding the need easy availability of contraceptives, and rise in efforts from governments to increased awareness regarding contraceptives. Changing lifestyles, rapidly melting social, religious, and ethical barriers, and late pregnancies are also leading to a significant surge in the uptake of oral contraceptive pills globally.

Buy Now “Oral Contraceptive Pills Market ” Research Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=8323&ltype=S

However, the market continues to be limited by social and religious barriers across a number of conservative developed as well as developing countries. Thus a large population of women across the globe confined by these factors is either unable to acquire contraceptives or are required to abstain from the usage of any form of contraceptives.

These factors could hamper the growth of the market to a certain degree over the report’s forecast period. Stringent regulations and policies associated with reproductive rights could also challenge the growth of the oral contraceptive pills market in certain countries in the near future.

0 votes

Several top players in the generic injectables market are focusing on mergers and acquisitions to consolidate their shares. They are also making substantial investment in research and development activities with an aim to develop new products, in order to gain an edge over their competitors, notes Transparency Market Research (TMR). Some of the companies holding leading positions in the market are Biocon Limited, Sanofi, Lupin Ltd., Hikma Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Mylan N.V., Fresenius SE & Co. KGaA, Baxter, Novartis AG (Sandoz International GmbH), and Pfizer Inc.A growing number of producers of generic injectables are focusing on products that meet the highest standard of efficacy and safety as that of the originator products.

The global generic injectables market is projected to expand rapidly from its worth of US$ 49.0 billion in 2016 to reach a worth of over US$ 150 billion by 2025. This represents a robust CAGR of nearly 13.6% during the forecast period of 2017–2025.

The various product types can be grouped into ampoules, vials, premixes, and prefilled syringes. Of all the segments, the market for prefilled syringes is expected to rise at the most attractive CAGR during the assessment period. The higher precision of dose, ease of self-administration, and reduced wastage of products are some of the compelling benefits accounting for their widespread acceptance.

Request PDF Sample of Generic Injectables Market Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=42698

Regionally, Asia Pacific led the global market in 2016 with substantial uptake of generic injectables among patient populations. The regional market is anticipated to rise at a rapid pace, attributed to the widespread demand for affordable therapeutics and sustained governmental thrust in key economies.

Demand for Affordable Quality Therapeutics propels Demand for Generic Injectable

The continued drive for generic injectable gains strength from the pressing need for quality therapeutics at affordable prices among patient populations world over, amid the soaring healthcare cost. The loss of patents for various blockbuster biological molecules in the years to come, coupled with the broadening acceptance of biologics, is a notable aspect propelling the demand for generic injectables. Spiraling spending on research and development of biologics is providing a large impetus to the growth of the market.

Broadening Acceptance of Prefilled Syringes as Advanced Drug Delivery System adds Sizeable Market Revenue

Efforts to bring constant innovation in drug delivery mechanism for injectables are catalyzing the demand for generic injectables. In this regard, the widespread acceptance of prefilled syringes among healthcare workers and patient populations at large is providing a robust impetus to the market’s growth. The number of attractive benefits drug delivery method has with the use of prefilled syringes has bolstered their uptake in parenteral drug delivery across the globe.

Furthermore, constant technological advances in drug delivery systems, especially in developed countries, is notably accentuating the growth of the market. Recent advances in the delivery mechanism of complex therapeutic molecules has imparted a noticeable momentum to the market’s growth.

Enquiry for Discount on “Generic Injectables Market ” Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=42698

Strict Regulatory Frameworks Hindering New Entrants, Oncology Biosimilars to open Promising Avenue

However, the market also suffers from certain setbacks. The high cost of investment required for setting manufacturing plants has constrained the entry of new players. Furthermore, a stringent regulatory framework with respect to large molecule generic injectables in developed countries, such as the U.S., is also hindering the market’s growth.

Nevertheless, the rapidly rising demand for lower-cost generic versions of vital medications among clinicians and patients will continue adding to the global revenues. A number of manufacturers or producers are putting their focus toward the area of oncology therapeutics. To this end, prominent players are making sizeable investment in R&D in oncology biosimilars to be delivered in injectable form. This will provide sustained fillip to the growth of the market over the forecast period.

0 votes

Several top players in the generic injectables market are focusing on mergers and acquisitions to consolidate their shares. They are also making substantial investment in research and development activities with an aim to develop new products, in order to gain an edge over their competitors, notes Transparency Market Research (TMR). Some of the companies holding leading positions in the market are Biocon Limited, Sanofi, Lupin Ltd., Hikma Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Mylan N.V., Fresenius SE & Co. KGaA, Baxter, Novartis AG (Sandoz International GmbH), and Pfizer Inc.A growing number of producers of generic injectables are focusing on products that meet the highest standard of efficacy and safety as that of the originator products.

The global generic injectables market is projected to expand rapidly from its worth of US$ 49.0 billion in 2016 to reach a worth of over US$ 150 billion by 2025. This represents a robust CAGR of nearly 13.6% during the forecast period of 2017–2025.

The various product types can be grouped into ampoules, vials, premixes, and prefilled syringes. Of all the segments, the market for prefilled syringes is expected to rise at the most attractive CAGR during the assessment period. The higher precision of dose, ease of self-administration, and reduced wastage of products are some of the compelling benefits accounting for their widespread acceptance.

Request PDF Sample of Generic Injectables Market Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=42698

Regionally, Asia Pacific led the global market in 2016 with substantial uptake of generic injectables among patient populations. The regional market is anticipated to rise at a rapid pace, attributed to the widespread demand for affordable therapeutics and sustained governmental thrust in key economies.

Demand for Affordable Quality Therapeutics propels Demand for Generic Injectable

The continued drive for generic injectable gains strength from the pressing need for quality therapeutics at affordable prices among patient populations world over, amid the soaring healthcare cost. The loss of patents for various blockbuster biological molecules in the years to come, coupled with the broadening acceptance of biologics, is a notable aspect propelling the demand for generic injectables. Spiraling spending on research and development of biologics is providing a large impetus to the growth of the market.

Broadening Acceptance of Prefilled Syringes as Advanced Drug Delivery System adds Sizeable Market Revenue

Efforts to bring constant innovation in drug delivery mechanism for injectables are catalyzing the demand for generic injectables. In this regard, the widespread acceptance of prefilled syringes among healthcare workers and patient populations at large is providing a robust impetus to the market’s growth. The number of attractive benefits drug delivery method has with the use of prefilled syringes has bolstered their uptake in parenteral drug delivery across the globe.

Furthermore, constant technological advances in drug delivery systems, especially in developed countries, is notably accentuating the growth of the market. Recent advances in the delivery mechanism of complex therapeutic molecules has imparted a noticeable momentum to the market’s growth.

Enquiry for Discount on “Generic Injectables Market ” Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=42698

Strict Regulatory Frameworks Hindering New Entrants, Oncology Biosimilars to open Promising Avenue

However, the market also suffers from certain setbacks. The high cost of investment required for setting manufacturing plants has constrained the entry of new players. Furthermore, a stringent regulatory framework with respect to large molecule generic injectables in developed countries, such as the U.S., is also hindering the market’s growth.

Nevertheless, the rapidly rising demand for lower-cost generic versions of vital medications among clinicians and patients will continue adding to the global revenues. A number of manufacturers or producers are putting their focus toward the area of oncology therapeutics. To this end, prominent players are making sizeable investment in R&D in oncology biosimilars to be delivered in injectable form. This will provide sustained fillip to the growth of the market over the forecast period.

0 votes

For players to stay ahead of competition within the global tuberculosis testing market, Transparency Market Research (TMR) has observed that strategic mergers and acquisitions have become the path. Mergers and acquisitions are helping companies to reach to newer markets as well as benefit from enhanced product portfolio. The betterment of products is becoming an important objective of leading companies for retaining their strong hold in the market. Leveraging on opportunities offered by government for conducting research on tuberculosis testing, players within the global tuberculosis testing market are growing.

Leading players within the market are: Hain Lifescience GmbH, Danaher Corporation, Thermo Fisher Scientific Inc., Epistem plc, Oxford Immunotec Ltd, Hologic Inc., Becton, F. Hoffmann-La Roche Ltd., Abbott Laboratories, QIAGEN, Akonni Biosystems Inc., Creative Diagnostics, Alere Inc., Cepheid, bioMérieux SA, and LIONEX Diagnostics & Therapeutics GmbH.

Request PDF Sample of Tuberculosis Testing Market Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2267

Asia Pacific Emerging as Leading Market for Tuberculosis Testing

As per a report by Transparency Market Research, the global tuberculosis testing market is anticipated to be worth US$3.18 bn by 2025, expanding at a mere 3.9% CAGR between 2017 and 2025. By geography, the market is led by Asia Pacific, which is estimated to expand at a 4.9% CAGR from 2017 to 2025. On the basis of type, the market is led by the culture based tests is leading and is likely to continue to do so throughout the forecast period on account of the ability to accurately diagnose and confirm active tuberculosis.

Hospital Laboratories and Physician’s Office Laboratories Generating High Demands for Tuberculosis Testing 

On the basis of end users, the market generates maximum revenues from the hospital laboratories market. The cost effective tests offered by hospital laboratories is the reason behind the leading status of this segment. The physician’s office laboratories segment is also a key end user segment.

Stuck In A Neck-To-Neck Competition With Other Brands? Buy Now “Tuberculosis Testing Market” Research Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=2267&ltype=S

Efforts by Government and Non-Governmental Organizations to Spread Awareness Regarding Tuberculosis Meets Success

As per the WHO, 10.4 mn new cases of tuberculosis had been registered in 2015. 56% of these cases comprised of men. The growing incidences of this disease is boding well for the growth of the global tuberculosis testing market. The market also benefits from the increasing awareness among the masses spread through constant efforts by governments and non-governmental organizations. Governments are also offering fee waivers and tax credits.

...